AstraZeneca's Truqap Faces Setback in Phase III Prostate Cancer Trial

AstraZeneca has discontinued the CAPItello-280 Phase III trial for Truqap in metastatic castration-resistant prostate cancer (mCRPC)124
The trial was unlikely to meet its dual primary endpoints of overall survival and radiographic progression-free survival24
This is the second Phase III failure for Truqap, following the CAPItello-290 trial in triple-negative breast cancer that failed in June 202424
Despite these setbacks, AstraZeneca CEO Pascal Soriot maintains that Truqap can still achieve $1-3 billion in annual sales, though with reduced potential5
Truqap generated $132 million in Q1 2025, falling 17% below consensus estimates2
The drug did succeed in the CAPItello-281 trial for patients with PTEN-deficient de novo metastatic hormone-sensitive prostate cancer in November 202424

#

Sources:

1. https://www.astrazeneca.com/media-centre/press-releases/2025/update-on-capitello-280-phase-iii-trial.html

2. https://www.biospace.com/drug-development/astrazenecas-truqap-posts-another-pivotal-disappointment-as-phase-iii-prostate-cancer-study-fails

4. https://www.clinicaltrialsarena.com/news/truqap-fails-phase-iii-study/

5. https://www.fiercepharma.com/pharma/astrazenecas-highly-touted-truqap-flunks-another-phase-3-trial